ANIP250117C60000
- 0.48
- 0.000.00%
ANI Pharmaceuticals Newsroom
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
ANI Pharmaceuticals Launches Generic Version of Motegrity
Express News | ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets With 180-Day Cgt Exclusivity
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Ani Pharmaceuticals Insider Sold Shares Worth $418,425, According to a Recent SEC Filing
ANI Pharmaceuticals (NASDAQ:ANIP) Has A Somewhat Strained Balance Sheet
ANI Pharmaceuticals Initiated at Outperform by Leerink Partners
Leerink Partners Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $80
Intrauterine Devices Market Report Forecasts and Company Analysis 2024-2032, Profiles of AbbVie, Bayer, Teva Pharmaceuticals, ANI Pharmaceuticals, Mylan, CooperSurgical. and DKT International
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect?
ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock?
ANI Pharmaceuticals Advances Amidst Regulatory and Market Challenges
Have ANI Pharmaceuticals Insiders Been Selling Stock?
Ani Pharmaceuticals Insider Sold Shares Worth $375,050, According to a Recent SEC Filing
US Manufacturing Index Rises To 43, Highest Since 2020
ANI Pharmaceuticals Price Target Maintained With a $94.00/Share by HC Wainwright & Co.
ANI Pharmaceuticals Analyst Ratings
Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Maintains Target Price $62